Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking ...

Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg ...

It is joining the initial public offering (IPO) queue amid a flurry of IPO activity in the sector, with three biotechs ...

The novel drugs work by mimicking the gut hormone GLP-1, which lowers blood sugar and limits the appetite. Treatments such as ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

ECG receives fees for speaking or consulting from Vyaire, BioAge, Stimit, Lungpacer Medical, Getinge, Draeger, Heecap, and Zoll. He serves on the clinical advisory board for Getinge and previously ...

A well-chosen name can carry an idea a long way. That’s especially true in tech, where names become verbs, and the same logic applies to companies, firms, and strategies—and I’d argue Avid Ventures’ ...